OPIOID RECEPTOR SUBTYPE ROLES IN FEEDING BEHAVIOR

这种竞争性的更新检查阿片受体的参与， 与肥胖、食欲、 控制、监管挑战和适口性。 摄食抑制 一般阿片受体拮抗剂对大鼠行为的影响未能说明 所涉及的亚型。 μ（β- FNA）、mu 1（纳洛嗪）、kappa（去甲-双那托酚胺; Nor-BNI）和δ（[D-Ala 2，Leu 5，Cys 6]-脑啡肽（DALCE）;纳曲吲哚） 阿片受体亚型在最初的拨款中使用。 军衔- 阿片受体亚型抑制摄入的顺序效力 拮抗剂是：a）自由进食（一般= kappa大于mu = mu 1 其远大于δ）; B）剥夺喂养（一般= mu = μ 1大于κ，κ远大于δ）; c）2- 脱氧-D-葡萄糖摄食过多（μ 2大于一般= κ， 大于δ，其大于μ 1）; d）胰岛素摄食过多（μ 2 比一般的大得多，一般的大于kappa = delta = mu 1）; e） 高脂肪摄入（kappa大于一般，一般大于mu 2 大于Δ，Δ大于μ 1）; f）蔗糖摄入量 （一般= kappa，其大于mu 2，其大于delta = μ 1）和g）缺水摄入量（一般大于μ 2， 大于κ，其远大于δ = μ 1）。 这 竞争性更新将评估B-FNA，纳洛嗪，Nor- BNI、DALCE、纳曲吲哚和纳曲酮对大量营养素选择的影响， 代谢笼中的总体摄食输入和输出、体温 和自发活动以及摄入。 的 多种κ受体亚型激动剂的不同作用-U 50，488 H (K1)和纳洛酮苯甲酰腙（K3）-将评价其 对剥夺、葡萄糖缺乏和适口性的中枢刺激作用 摄入 将对上述阿片受体亚型拮抗剂进行评价 对正常大鼠饮用盐水的影响，以及对 用血管紧张素II或高渗盐水攻击的大鼠。 最后， 长效阿片受体亚型拮抗剂的慢性作用将 在正常的，遗传的， 暴露于正常或可口饮食的肥胖或饮食性肥胖大鼠。

This competitive renewal examines the involvement of opioid receptor subtypes on ingestive behaviors related to issues of obesity, appetite control, regulatory challenges and palatability. Inhibition of ingestive behavior in rats by general opiate receptor antagonists failed to specify the subtypes involved. Specific antagonists of the mu (beta- funaltrexamine; B-FNA), mu1 (naloxonazine), kappa (nor-binaltor-phamine; Nor-BNI) and delta ([D-Ala2, Leu5, Cys6]-enkephalin (DALCE); naltrindole) opioid receptor subtypes were employed in the original grant. The rank- order potencies of inhibition of intake by opioid receptor subtype antagonists are: a) free feeding (general = kappa is greater than mu = mu1 which is much greater than delta); b) deprivation feeding (general = mu = mu1 which is greater than kappa which is much greater than delta); c) 2- deoxy-D-glucose hyperphagia (mu2 greater than general = kappa which is much greater than delta which is greater than mu1); d) insulin hyperphagia (mu2 is much greater than general which is greater than kappa = delta = mu1); e) high-fat intake (kappa is greater than general which is greater than mu2 that is greater than delta which is greater than mu1); f) sucrose intake (general = kappa which is greater than mu2 which is greater than delta = mu1) and g) water deprivation intake (general is greater than mu2 which is greater than kappa which is much greater than delta = mu1). This competitive renewal will evaluate the effects of B-FNA, naloxonazine, Nor- BNI, DALCE, naltrindole and naltrexone upon macronutrient selection, overall ingestive inputs and outputs in a metabolic cage, body temperature and locomotor activity as well as intake in sham feeding rats. The differential roles of multiple kappa receptor subtype agonists - U50, 488H (K1) and naloxone benzoylhydrazone (K3) - will be evaluated for their central stimulatory effects upon deprivation, glucoprivic and palatable intake. The above opioid receptor subtype antagonists will be evaluated for effects upon saline drinking in normal rats, and for fluid intake in rats challenged with either angiotensin II or hypertonic saline. Finally, the chronic effects of long-acting opioid receptor subtype antagonists will be evaluated for changes in intake and body weight in normal, genetically- obese or dietary-obese rats exposed to normal or palatable diets.